Printer Friendly
The Free Library
21,436,143 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Anemia drugs may speed growth of cancer.

According to new studies, drugs used widely to treat anemia in cancer patients may actually speed progression of the cancer in certain individuals, "The Washington Post" reported June 2.

Recent controversy over erythropoiesis-stimulating agents (ESAs) such as Procrit, Epogen and Aranesp has centered on whether the blood-boosting drugs should be withdrawn from the market because of troubling side effects Side effects

Effects of a proposed project on other parts of the firm.
.

In March, an FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 advisory panel voted to recommend continued use of the drugs for patients on chemotherapy, unless the patient is likely to be cured. They also voted to recommend against the drugs' use in patients with breast or head and neck cancer.

The drugs' manufacturers added a "black box" warning to the medications last November. Eight clinical trials now suggest these medications actually speed the growth of tumors and shorten the lives of cancer victims, the Post reported.

The results of the current study were based on analyses of tumor samples from 101 patients diagnosed with head and neck cancer who had participated in a previous phase III trial of erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production . Scientists measured levels of erythropoietin receptor (EpoR) messenger RNA mes·sen·ger RNA
n.
See mRNA.
 (mRNA). High levels of EpoR mRNA in patients who had undergone radiation but not surgery tended to signal a worse prognosis. There was a similar effect with Janus Kinase 2 (Jak2), the main intermediary of EpoR signaling.

A second study found the multiple drugs elderly cancer patients may already be taking could interact significantly with chemotherapy.

In particular, patients taking drugs that interfered with protein binding, such as Norvasc for high blood pressure, Prilosec for heartburn heartburn, burning sensation beneath the breastbone, also called pyrosis. Heartburn does not indicate heart malfunction but results from nervous tension or overindulgence in food or drink.  and the pain reliever Celebrex, were more likely to experience hematologic hematological, hematologic

pertaining to or emanating from blood cells.


hematological tests
total and differential white cell counts, hematocrit estimation, erythrocyte count.
 side effects such as low white blood cell counts.

Patients taking drugs that act on a group of enzymes known as cytochrome cytochrome (sī`təkrōm'), protein containing heme (see coenzyme) that participates in the phase of biochemical respiration called oxidative phosphorylation.  p450 were more likely to experience effects such as fatigue or diarrhea. Examples of these drugs include the heart medications such as Pacerone and Cordarone.
COPYRIGHT 2008 Washington Information Source, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Adverse Event Reporting News
Geographic Code:1USA
Date:Jun 17, 2008
Words:315
Previous Article:FDA reviewing arthritis drugs for childhood cancer link.
Next Article:Acomplia linked to deaths since approval in U.K.
Topics:



Related Articles
Anemia: a defense against cancer?
Cranking up cancer treatments: a bright future for growth factors.
EntreMed and Affymax form tissue factor pathway inhibitor peptides collaboration.
FDA strengthens safety information for ESAs.
Anemia treatment warnings.
FDA strengthens boxed warnings for high profile drugs-Avandia, and ESAs Aranesp, Epogen, and Procrit.
Agency receives new data for anemia drug risks.
Anemia drugs face increasing questions at FDA.
Medicare may limit coverage of anemia drugs.

Terms of use | Copyright © 2013 Farlex, Inc. | Feedback | For webmasters | Submit articles